Website: UbiVac
Business Area(s):
Description: Since 2005 the company has been engaged in the research, development and testing of therapeutic immunotherapy strategies to combat cancer and infectious diseases.
UbiVac’s lead product, DPV-001 (DRibble), is a first in class DC-targeted complex vaccine/combination immunotherapy that is “off-the-shelf” and in a National Cancer Institute-supported Phase II clinical trial for the adjuvant treatment of non-small cell lung cancer (NSCLC). Results of this clinical trial document that DPV-001 induces and/or boosts the immune response in every patient who received the vaccine.
Location(s):
Portland
OR
United States
See map: Google Maps